Mizuho Securities analyst Difei Yang reiterated a Hold rating on Alder Biopharmaceuticals (ALDR) today. The company’s shares closed last Monday at $10.06.
Yang observed:
“We see the deal as a nice exit for Alder shareholders, and we believe Alder’s assets represent a good strategic fit for Lundbeck. We believe probability of EU approval is fairly high and the only potential source of uncertainty we see may revolve around manufacturing (more below).”
According to TipRanks.com, Yang is a 4-star analyst with an average return of 4.2% and a 39.7% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Audentes Therapeutics, and Revance Therapeutics.
Alder Biopharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $19.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.15 and a one-year low of $8.39. Currently, Alder Biopharmaceuticals has an average volume of 771.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy.
